Clinical trials: Immunocompromised Patients
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Invasive Aspergillosis, Other Fungal Infections
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by…
- Trial name
- NCT00158730
- Testing
- AmBisome
- Volunteers
- 800 people
- Sponsor
- Gilead Sciences
Infection, Infections, Bacterial
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection…
- Conditions
- Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
- Trial name
- OPTIMUM (NCT07110636)
- Testing
- Metagenomic plasma-based test for agnostic pathogen detection
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Karius, Inc.
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Immunodeficiency and Suspected Infection
Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.
The study patients are patients suffering from primary or secondary immunodeficiencies investigated in the Hospital Necker for a suspected infectious disease.
- Trial name
- PATHOQUEST1 (NCT02007642)
- Testing
- Blood sampling / Body fluid sampling
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Pathoquest
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients.
- Trial name
- NCT07690943
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- LucasBio
Respiratory Syncytial Virus Infection
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
This post marketing observational study (PMOS) was conducted in Japan during the 2013-2014 and 2014-2015 Respiratory Syncytial Virus (RSV) seasons to assess the safety and effectiveness of palivizumab for the prevention of…
- Trial name
- NCT02016690
- Volunteers
- 312 people
- Sponsor
- AbbVie
Respiratory Syncytial Virus
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years.
- Trial name
- NCT06067230
- Testing
- mRNA-1345
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 1,153 people
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Infections
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
- Trial name
- NCT07092865
- Testing
- Adjuvanted RSVPreF3 vaccine
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- GlaxoSmithKline
Fungal Infection
Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)
This is an open-label study of MK0991 in children between 3 to 24 months of age with new onset fever and neutropenia. The purpose of the study is to investigate plasma drug levels of caspofungin.
- Trial name
- NCT00292071
- Testing
- caspofungin acetate
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Fungal Infections
A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)
The purpose of this dose-escalation study is to evaluate the pharmacokinetics, safety, and tolerability of oral posaconazole in immunocompromised children with neutropenia or expected neutropenia.
- Trial name
- NCT01716234
- Testing
- Posaconazole 12 mg/kg/day BID, Posaconazole 18 mg/kg/day BID, Posaconazole 18 mg/kg/day TID
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)
This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) receiving chemotherapy and to assess the impact of V212 on…
- Trial name
- NCT01254630
- Testing
- V212
- Volunteers
- 5,305 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer
Influenza, Human
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the…
- Trial name
- NCT00545532
- Testing
- oseltamivir
- Where
- 208 sites in United States, Argentina and 24 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Invasive Fungal Disease, Fever and Neutropenia
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.
- Conditions
- Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
- Trial name
- NCT03262584
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Karius, Inc.
RSV Infection
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised…
- Trial name
- MUSIC (NCT04484935)
- Testing
- Nirsevimab
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Smallpox
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
The main purpose of this clinical trial is to generate additional safety data in a highly immunocompromised population. HIV-infected persons are considered excellent candidates to represent the highly immunocompromised population…
- Trial name
- NCT02038881
- Testing
- IMVAMUNE®
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Bavarian Nordic
COVID-19
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
The primary objective of this study is to evaluate efficacy of plitidepsin in pre-specified groups of immunocompromised patients with symptomatic COVID-19 requiring hospital care versus control in terms of mortality.
- Trial name
- NEREIDA (NCT05705167)
- Testing
- Plitidepsin
- Where
- 44 sites in Belgium, France and 9 more
- Volunteers
- 37 people
- Sponsor
- PharmaMar
Influenza
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed…
- Trial name
- NCT01715909
- Testing
- Oseltamivir
- Where
- 50 sites in United States, Belgium and 13 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche